Lau EMC, Dinavahi R, Woo YC, et al. - Since romosozumab, a sclerostin antibody, exerts dual effect to increase bone formation and decrease bone resorption. In high-risk postmenopausal osteoporotic women vs alendronate alone, the global ARCH study showed superiority of romosozumab followed by alendronate in reducing fracture risk. Researchers describe outcomes among ARCH East Asian individuals. A sum of 275 individuals were recruited from Hong Kong, Korea, and Taiwan. The primary outcomes included incidence of new vertebral fracture (VF) at 24 months and clinical fracture at primary analysis (confirmed fractures in ≥ 330 individuals and all individuals had the opportunity to attend month 24 visit). Among East Asian individuals, results demonstrated that romosozumab followed by alendronate was correlated with lower incidences of new vertebral, clinical, non-vertebral, and hip fractures vs alendronate alone.